Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations

E. Ondroušková, M. Bohúnová, K. Závacká, P. Čech, P. Šmuhařová, M. Boudný, M. Oršulová, A. Panovská, L. Radová, M. Doubek, K. Plevová, M. Jarošová

. 2022 ; 12 (-) : 859618. [pub] 20220624

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22023826

Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM, is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups with diverse prognoses. Gain of 8q24 is one of the abnormalities considered as prognostically unfavorable. In our study, we performed a FISH analysis in an initial cohort of 303 consecutive CLL patients and determined the frequency of +8q to be 6.3 %. Our analysis confirmed the association with TP53/ATM aberrations and CK, as the frequency of +8q reached 26.7 % in an extended delTP53/ATM+CK cohort. M-FISH analysis enabled the identification of partner chromosomes where the segment of the duplicated 8q arm was localized. More detailed mapping of the gained 8q region using the M-BAND method determined the smallest amplified region 8q23-8qter. We observed significantly shorter overall survival (OS; 9.0 years in +8q-positive vs. 10.6 years in +8q-negative; p=0.02) and detected slightly higher MYC mRNA/protein levels in +8q-positive vs. +8q-negative patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22023826
003      
CZ-PrNML
005      
20240122102250.0
007      
ta
008      
221010s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fonc.2022.859618 $2 doi
035    __
$a (PubMed)35814434
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Ondroušková, Eva $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
245    10
$a Duplication of 8q24 in Chronic Lymphocytic Leukemia: Cytogenetic and Molecular Biologic Analysis of MYC Aberrations / $c E. Ondroušková, M. Bohúnová, K. Závacká, P. Čech, P. Šmuhařová, M. Boudný, M. Oršulová, A. Panovská, L. Radová, M. Doubek, K. Plevová, M. Jarošová
520    9_
$a Chronic lymphocytic leukemia (CLL) with cytogenetics findings, such as complex karyotype and deletions of TP53 or ATM, is associated with adverse clinical outcomes. Additional chromosomal abnormalities further stratify patients into groups with diverse prognoses. Gain of 8q24 is one of the abnormalities considered as prognostically unfavorable. In our study, we performed a FISH analysis in an initial cohort of 303 consecutive CLL patients and determined the frequency of +8q to be 6.3 %. Our analysis confirmed the association with TP53/ATM aberrations and CK, as the frequency of +8q reached 26.7 % in an extended delTP53/ATM+CK cohort. M-FISH analysis enabled the identification of partner chromosomes where the segment of the duplicated 8q arm was localized. More detailed mapping of the gained 8q region using the M-BAND method determined the smallest amplified region 8q23-8qter. We observed significantly shorter overall survival (OS; 9.0 years in +8q-positive vs. 10.6 years in +8q-negative; p=0.02) and detected slightly higher MYC mRNA/protein levels in +8q-positive vs. +8q-negative patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bohúnová, Michaela $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $7 xx0281019
700    1_
$a Závacká, Kristýna $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia
700    1_
$a Čech, Patrik $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Šmuhařová, Petra $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Boudný, Miroslav $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia
700    1_
$a Filipová, Martina $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $7 xx0313005
700    1_
$a Panovská, Anna $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Radová, Lenka $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Plevová, Karla $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia $u Center of Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czechia $u Institute of Medical Genetics and Genomics, Faculty of Medicine, Masaryk University, Brno, Czechia
700    1_
$a Jarošová, Marie $u Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czechia
773    0_
$w MED00182989 $t Frontiers in oncology $x 2234-943X $g Roč. 12, č. - (2022), s. 859618
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35814434 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20221010 $b ABA008
991    __
$a 20240122102248 $b ABA008
999    __
$a ind $b bmc $g 1854040 $s 1175114
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 12 $c - $d 859618 $e 20220624 $i 2234-943X $m Frontiers in oncology $n Front Oncol $x MED00182989
LZP    __
$a Pubmed-20221010

Najít záznam

Citační ukazatele

Možnosti archivace